Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New posters pumping a lame interview. Everyone who hears the interview is depressed. Why are they pumping this interview. To quote a famous penny player
"Are you saying that my disingenuosity is anything other than disingenuous"
I think this hits .10 soon. No one is buying that interview. People are selling that interview and new posters are directing your attention to it. see quote above...BUY...IMWO
Steel :)
Quick. I don't think they will answer you anymore. But if they do, see if you can get a DNA sample...Just joking. Anyway the reason people are holding bags here, myself included is bad timing. PKTO is just another pink sheeter. If it shocks me and ends up as a real company, that's fine also....
I will say again, that I find it extremly odd that the CEO would submit himself to such an awkward process. Nothing is what it appears to be on the pinks. Maybe it is time to buy
steel, why would he submit to the interview if that was all he had. very strange
The audited financials. It is a mantra from hell on the pinks. They are waiting for them over at #$JB and $%YS and countless other virtual locations. Please don't bring up that thread here. This board is hard enough to read. It is not my intention to be mean spirited but we will probably see mug shots here before AF's...All IMWO...the w stands for worthless
steel..this is the bottom. You will in all liklihood see .01 again so if you have powder load up and get even. I have no powder
ecfl and pkto sames pps...youzer
you are an animal :) gl
is everybody happy
his mistake is he thinks penny players only play penny stocks. A fool
I agree that it may not be dillution but it doesn't matter. He went public to try and get some money back into the pockets of the original investors. I f anyone is going to make money it is them. He used a public vehicle but despises the common shareholder. That will come back to haunt him even if he does start to generate cash flow Look at what ltrx did to their shareholders as they tried to gain a foothold in the public markets. The public never forgets contempt and this guy will rue the day he mocked the penny investor. You do not go from pennies to multi dollars with out passsing through .01 then .10 then .50 and 2.00 and he will be ignored.
There are hundreds of stocks that make money and people ignore. This will be another. No I don't think it is a scam but I do think the CEO is stupid.
Quikfix thank you for all your dd. From it I get the strong feeling that they will completely disregard current shareholders when the pie is cut. We are here because when you reverse and go public we are here but they have no intention of throwing the dog a bone. IMO. They will issue enough restricted shares to give the initial investors big money and a percent or two for us. The penny money that was to be made here has been made and the highs have come and gone. If you want to buy this as a long term investment you should wait till ALL the numbers are out. Hunting for a momo...Not here. IMO....glta I won't selling because I don't need a new pair of sneakers. Once again..Buy high suck wind
better yet start accumillating now quietly...shhhh...and tell your boys to fuel the breakout on the next pr and we could get a nice momo to .20..
vshd board 12th......i post here so you can understand mondays prediction a bit
Posted by: smallcapwhiz
In reply to: None Date:3/12/2007 1:47:41 PM
Post #of 239
Im going to have my group of daytraders come in with some heavy buying on the ask in the next 30 min. Keep an eye out. Get in while its low.
ENXTF..how high will it go....CLRT buy buy buy buy IMO
quik you cleaned out the double zeros. Everyone showing up now got to cough up a penny..NICE BUY...imo
looks like no more 00 shares available
was that your trade just reinstated
Light. I have never seen anything like that and would be interested in what you here back if anything. Do over trades. That is scary
I have been reading the CKYS board..Amazing..Just to think that it was the profit I made from CKYS as it went from .016 to .033 that gave me the money I put on FCCN..Remember I made 22k on FCCN. Where is that money now??
.008 i hope
If that happens here I'll cry for joy
Concerning The pm..I think I would sell it just to book a plus trade.
IP CLRT will make us look smart ..IMO
I am almost afraid to answer. obviously some shares avoided restriction...gulp
Ah yes ...funds. Too bad funds don,t grow on trees like figs and other fruits.
Jup someone keeps hitting the 8's whenever it gets there. Wish I could add here. I am learning. This will go back up and the buyers at this level are very safe..gl
I like JAVO after looking at it. all those warrants at 1.79 and beyond. They have had that cash to build out there business and will probably soon announce revenue increases as a result of the influx of cap..imo.. . It seems to have stabilized and has those warrant holders at a 1.79 and beyond. Love th products and clients(7-11). I give you my blessing BUY
JAV dd
Javelin Pharmaceuticals Signs Commercial Supply Agreement with Precision Pharma Services
2/26/2007 9:20:22 AM
New York-Based Contract Manufacturer to Supply Dyloject(TM) for Launch in Europe
CAMBRIDGE, Mass., Feb 26, 2007 (BUSINESS WIRE) -- Javelin Pharmaceuticals, Inc. ( JAV ), a leading developer of novel products for pain control, today announced it has signed a Commercial Supply Agreement with Precision Pharma Services, Inc. Under the Agreement, Precision will manufacture vials of Javelin's injectable Dyloject(TM) product (diclofenac sodium 75mg / 2mL) for use in Javelin's anticipated European markets pending regulatory approval. The Agreement has a two-year, renewable term and sets forth minimum purchase and production requirements.
"This agreement is an important step forward in growing Javelin's manufacturing infrastructure in anticipation of initial product sales later this year in Europe," said Michael Moshman, Javelin's Vice President for Clinical and Commercial Manufacturing. "Working with Precision Pharma will enable us to marshal the resources to meet future demand for Dyloject as we begin commercializing this promising analgesic with its launch in the UK in 2007."
About Javelin Pharmaceuticals, Inc.
With US corporate headquarters in Cambridge, MA, and a European office in Cambridge, UK, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the website at www.javelinpharmaceuticals.com.
About Precision Pharma Services, Inc.
Pr
IPRE..look at what JAV has done
some dd
Pinnacle Digest: Subsidiary Recieves License: Spurs Review
3/13/2007 5:06:06 AM
Mar 13, 2007 (M2 PRESSWIRE via COMTEX) -- To read this review in its entirety, please visit www.pinnacledigest.com.
Javelin Pharmaceuticals, Inc. ( JAV ) experienced a slight increase of 0.54% accompanied by 210,200 shares traded. They recently announced that the British Medicines and Healthcare Products Regulatory Agency (MHRA) have granted a Wholesale Dealer's License to Javelin's UK subsidiary, Javelin Pharmaceuticals UK Limited. PinnacleDigest is looking closely into this License as it will enable Javelin Pharmaceuticals UK to expand and promote their products accordingly.
As stated in past articles acquisitions and alliances of biotechnology companies have been on the rise of late. This fact becomes very clear when reviewing the figures of last year. Bigger drug makers can foresee a future in which the environment and demand for drugs is a very positive one over the coming 25 years.
At PinnacleDigest we strive to not only bring you an unbiased, informative, broad approach to the industry, but to specifically analyze specific companies in respect to that approach. The first step in this process is to review the company in contrast to the influences within the sector affecting them. To continue with this review in its entirety, come explore our growing online financial magazine at www.pinnacledigest.com.
Rep. Patrick Kennedy is planning to initiate the use of personal health records through a trust fund that pays doctors. The new version of his bill was introduced March 1.
It is known as the Personalized Health Information Act and would require the Department of Health and Human Services to create a public-private PHR incentive program and trust fund to pay physicians. Physicians would be paid up to three years and at least $3 per eligible patient enrolled to use a PHR. We will come back to this issue and its possible long term affects on this company and the healthcare sector.
In respect to Javelin Pharmaceuticals this new license for the subsidiary represents a key commercialization step in anticipation of the product launch for Dyloject (diclofenac sodium 75mg / 2mL). Dyloject is currently under review for Marketing Authorization Application (MAA) approval in the UK also by the MHRA. This approval will be awaited with great anticipation by our team at PinnacleDigest. We will also be closely monitoring the relevant market and this drugs potential integration into it. To follow up with Javelin Pharmaceuticals and to learn more about the sector which influences them so greatly, visit us at www.pinnacledigest.com.
To continue with this report as well as other related articles, please visit www.pinnacledigest.com for a complimentary membership. It should be stated that our membership requires no commitment to our service. If you would like to contact us please write to support@pinnacledigest.com.
PinnacleDigest has no vested interest in the company mentioned herein. This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.
Investors seeking a distinctive approach to investing should also visit www.pinnacledigest.com for a complimentary membership.
About Pinnacle Digest
Pinnacledigest.com is an emerging online financial newsletter community. We put together informative material, capturing the information that we know will give you an edge to your portfolio and more specifically your investment approach.
Once a member of PinnacleDigest you will be able to access our complimentary full-length research reports on selected companies, our weekly volumes, and our market overviews. In addition to these services we are confident you will enjoy our many other services, as well as our main feature which is available to all our members.
We pride ourselves in having a multi purpose online magazine and encourage you to join our community.
This
Great e-mail..Thanks...The guys got a good read on the pinks...I wish him luck. I have 75k shares . I,ll just forget them for a while.
ANWM is consolidating on these levels and offers the same kind of upside as your beloved JLNY IMO
IPRE check out the goings on at RYQG. I am not rec'ing a buy just bringing it to your attention
CLRT...I think I like it better than ENXTF....I'm sure I do...
CLRT....Fifth consecutive quarter of double digit growth.
Inc (NASDAQ CM) 3/14/2007 12:00:00 AM ET
Realtime Quote $1.85 + $0.11 (+6.32%) Refresh Quote
Press Release for Clarient Inc
Safeguard Executes Game Plan, Announces Profit for 2006, Generates 31% Increase in Fourth Quarter 2006 Revenues
3/8/2007 6:00:24 AM
Well-Timed Exits, Ignited Deal Machinery, Augmented Organization Generate Momentum for 2007
WAYNE, Pa., Mar 08, 2007 (BUSINESS WIRE) -- Safeguard Scientifics, Inc. ( SFE ), which builds value in growth-stage technology and life sciences companies, today announced its financial results for the fourth quarter and year-end 2006. In 2006, Safeguard executed upon its game plan to reposition itself as a holding company, to time exits for maximum risk-adjusted value, to ignite its deal machinery and to augment its organization. Through the sale of its holdings in Mantas and Traffic.com, Safeguard realized profitability for 2006, positioning the company to be able to deploy capital and continue to build value in its partner companies.
Safeguard reported consolidated revenues of $53.3 million for the fourth quarter of 2006, a 31% increase as compared to $40.7 million in 2005, adjusted for discontinued operations. This revenue growth represents the fifth consecutive quarter of double-digit revenue growth for Safeguard. For the full year, revenue was $198.1 million, up 38% from $143.8 million in 2005. Safeguard's consolidated net income for the fourth quarter of 2006 was $71.3 million, compared to $2.3 million in 2005. For the full year, net income was $46.0 million, compared to a net loss of $32.1 million in 2005.
"In 2006, we made significant strides toward executing upon our game plan. As a holding company, we ignited our deal machinery, identified opportunities and deployed capital in seven transactions," said Peter J. Boni, President and Chief Executive Officer of Safeguard. "Three of our new partners are technology-focused companies, Authentium, Portico Systems and Advantedge Healthcare Solutions; two are life sciences companies, Rubicor Medical and NuPathe. We also provided additional funding to support growth and product development at Acsis, while deploying additional capital and operational support for strategic acquisitions by Alliance Consulting and Clarient."
Boni continued, "Throughout the year, we built value in our partner companies. We augmented our Safeguard team, both internally and externally, with two advisory boards, together with key board-level and management additions, although we are searching for a permanent CFO. We also realized value from divesting some of our partner company holdings during 2006, which drove us to profitability for the fourth quarter and full year."
"Our successes in 2006 have established a foundation to support the transition into the second phase of our strategy. In 2007, we are focused on deploying capital, including the recently announced growth financing for Advanced BioHealing, Inc., a leader in regenerative medicine focused on the development and marketing of cell-based and tissue-engineered products. In addition, we're looking to build value in our holdings and realize that value in selective, well-timed exits, ultimately driving shareholder value," concluded Boni.
TECHNOLOGY PARTNER COMPANIES
Fourth Quarter Highlights - Majority Holdings
Acsis, Inc. extended its software solution within supply-chain management, growing its customer base 17% in 2006. Revenue for the fourth quarter was $5.5 million. In the fourth quarter, Acsis booked its strongest number of software licenses. Demand for its Acsis Line Manager was especially strong with over seventy stations sold. Throughout the year, Acsis focused its product development on emerging software markets, expanded strategic partnerships and built a world-class management team. Acsis re-architected its product portfolio and expects its expanding relationship with SAP(R) to help drive new business opportunities in 2007.
Alliance Consulting, Inc. posted $1.0 million of operating income in the fourth quarter. Revenue for the fourth quarter increased to $26.0 million, up 8% as compared to 2005. Alliance's year-over-year revenue growth far exceeded industry averages and its investment in growth areas such as Master Data Management has generated positive recognition by several industry analyst groups. Strong bookings in the fourth quarter enabled Alliance to start 2007 with solid backlog levels.
Pacific Title & Art Studio, Inc. was honored with an Academy Award for their innovative and proprietary digital archiving technology. In the fourth quarter, Pacific Title's revenue was $6.8 million, a decrease of 4% year-over-year. This is reflective of an overall decline in the movie production industry.
LIFE SCIENCES PARTNER COMPANIES
Fourth Quarter Highlights - Majority Holdings
Laureate Pharma, Inc. achieved record growth in 2006 with fourteen new client agreements and a twofold increase in backlog as compared to 2005. Fourth quarter revenue was up more than 200% year-over-year at $4.9 million. The company increased its workforce more than 25%, is on track to complete its facility expansion, and entered into key strategic alliances during the year. In addition, Laureate Pharma formed a Scientific Advisory Board comprised of well-respected industry leaders to help guide the company through its evaluation of new services and emerging technologies.
Clarient, Inc. ( CLRT ) reported significant growth in advanced cancer diagnostic services with decreasing losses. Revenue for the fourth quarter was $10.2 million, up 70% year-over-year. During the fourth quarter, Clarient reported that they have started realizing revenue from sales of their new Advanced Cellular Imaging System (ACIS(R) III) and received milestone payments for their development efforts.
very very good. Help is beautiful. I was not thinking of that one. I was thinking of Nowhere Man but help might be better.
doesn't anyone else want to sell..why stop now. Geesh it has been a humbling couple of weeks. ECFL and PKTO. two Beatle songs come to mind that describe my current trading condition..Can anyone guess them?
Oh my. You are making me dizzy..gl
Holy chit..IPRE..You made me famous. Well then, even though I have no play money. Watch me dd some winners for the board..Also..I think PKTO at this price is a steal. Wish I had waited and bought down here